NASDAQ · NOVTU
Technology · Hardware, Equipment & Parts
$61.64
Up+$0.56 (+0.92%)
Updated Sep 14, 2026, 2:25 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 18 trading sessions · Daily adjusted prices
NOVTU closed at $61.64 after 18 trading sessions, down 11.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $62.58 | $62.58 | $61.64 | $61.64 | 1.63K |
| Sep 10, 2026 | $60.78 | $61.15 | $60.77 | $61.08 | 1.42K |
| Sep 9, 2026 | $62.21 | $62.40 | $61.89 | $61.89 | 3.27K |
| Sep 8, 2026 | $63.40 | $64.29 | $63.38 | $63.59 | 2.46K |
| Sep 4, 2026 | $63.13 | $63.13 | $62.65 | $62.68 | 744.16 |
| Sep 3, 2026 | $62.32 | $62.32 | $61.62 | $61.62 | 837 |
| Sep 2, 2026 | $61.56 | $61.69 | $61.05 | $61.18 | 3.27K |
| Sep 1, 2026 | $60.73 | $61.04 | $60.59 | $60.92 | 9.44K |
| Aug 31, 2026 | $60.36 | $62.33 | $60.36 | $62.25 | 11.63K |
| Aug 27, 2026 | $60.85 | $61.64 | $60.83 | $61.64 | 2.32K |
| Aug 26, 2026 | $60.35 | $61.53 | $60.35 | $61.52 | 879 |
| Aug 25, 2026 | $60.00 | $60.00 | $59.83 | $59.91 | 1.89K |
| Aug 24, 2026 | $60.76 | $60.76 | $59.66 | $59.66 | 5.7K |
| Aug 21, 2026 | $61.90 | $62.26 | $61.37 | $62.26 | 1.73K |
| Aug 20, 2026 | $63.98 | $63.98 | $61.44 | $62.05 | 52.36K |
| Aug 19, 2026 | $65.00 | $65.10 | $61.93 | $61.93 | 109.82K |
| Aug 18, 2026 | $76.89 | $76.95 | $65.64 | $65.64 | 5K |
| Aug 17, 2026 | $75.00 | $75.00 | $68.66 | $69.565 | 5.13K |
The latest Smart Investors Daily articles mentioning NOVTU.
NOVTU research
Company profile and research snapshot.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Baird | Outperform | — |
| Mar 30, 2026 | Baird | Outperform | — |
| Aug 11, 2025 | Baird | Neutral | — |
| Mar 3, 2025 | Baird | Neutral | — |
| Nov 6, 2024 | Baird | Neutral | — |
No generated briefing is available yet.
ChartMill · Sep 1, 2026
Discover why Novanta (NOVTU) passes the Caviar Cruise quality screen: strong EBIT growth, 25.5% ROIC, and solid cash conversion.
Yahoo · Aug 28, 2026
BOSTON, August 28, 2026--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY.
Yahoo · Aug 27, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how electronic components stocks fared in Q2, starting with Novanta (NASDAQ:NOVT).
Yahoo · Aug 14, 2026
Novanta's second quarter was marked by broad-based organic growth across all business units and a favorable response from the market. Management attributed the strong results to both an acceleration in new product revenue—up more than 50% year-over-year—and operational improvements, including factory consolidations. CEO Matthijs Glastra highlighted that all business units grew organically and pointed to increased customer demand in precision robotics, AI-driven manufacturing, and minimally invas
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NOVTU.
